Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Approved For Marketing No phase listed Expanded access

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

ClinicalTrials.gov ID: NCT03070093

Public ClinicalTrials.gov record NCT03070093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Study identification

NCT ID
NCT03070093
Recruitment status
Approved For Marketing
Study type
Expanded access
Phase
Not listed
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Enrollment
Not listed

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
Apr 19, 2021

United States locations

U.S. sites
32
U.S. states
21
U.S. cities
26
Facility City State ZIP Site status
UCLA Los Angeles California 90095
Rocky Mountain Cancer Center-M Aurora Colorado 80012
Memorial Healthcare System Pembroke Pines Florida 33028
Northside Hospital Atlanta Georgia 30342
Georgia Cancer Center at Augusta University Augusta Georgia 30912
Northwestern University Medical Center Chicago Illinois 60611
University of Chicago Chicago Illinois 60637
Indiana Blood and Marrow Transplantation at Franciscan Health Indianapolis Indianapolis Indiana 45237
Norton Cancer Institute Louisville Kentucky 40207
Tulane University New Orleans Louisiana 70112
University of Maryland Medical Center Baltimore Maryland 21201
Johns Hopkins Hospital Baltimore Maryland 21287
The Sidney Kimmel Comprehensive Cancer Center -Johns Hopkins University Baltimore Maryland 21287
Massachusetts General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Dana Farber Cancer Institute Boston Massachusetts 02215
West Michigan Regional Cancer Center Kalamazoo Michigan 49007
Washington University School of Medicine St Louis Missouri 63110
New Mexico Cancer Care Alliance Albuquerque New Mexico 87106
Roswell Park Cancer Institute Buffalo New York 14263
Memorial Sloan Kettering New York New York 10021
Weill Cornell Medical College New York New York 10065
Duke University Medical Center Durham North Carolina 27710
Wake Forest Baptist Hospital Winston-Salem North Carolina 27157
Ohio State University Columbus Ohio 43210
Providence Portland Medical Center Portland Oregon 97213
Penn State Hershey Medical Center Hershey Pennsylvania 17033
Thomas Jefferson University Philadelphia Pennsylvania 19066
UPCI Pittsburgh Pennsylvania 15232
Vanderbilt University Nashville Tennessee 37232
Huntsman Cancer Institute University of Utah Salt Lake City Utah 84112
WVU Medicine Cancer Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03070093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03070093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →